Suppr超能文献

雷沙吉兰改善帕金森病患者的多导睡眠图睡眠参数:一项双盲、基线对照试验。

Rasagiline improves polysomnographic sleep parameters in patients with Parkinson's disease: a double-blind, baseline-controlled trial.

机构信息

Department of Neurology, Technische Universität Dresden, Dresden, Germany.

Interdisciplinary Sleep Laboratory, Technische Universität Dresden, Dresden, Germany.

出版信息

Eur J Neurol. 2018 Apr;25(4):672-679. doi: 10.1111/ene.13567. Epub 2018 Feb 27.

Abstract

BACKGROUND AND PURPOSE

The aim was to study the effects of rasagiline on sleep quality in patients with Parkinson's disease (PD) with sleep disturbances. Sleep disorders are common in PD. Rasagiline is widely used in patients with PD, but double-blind polysomnographic trials on its effects on sleep disturbances are missing.

METHODS

This was a single-center, double-blind, baseline-controlled investigator-initiated clinical trial of rasagiline (1 mg/day) over 8 weeks in patients with PD with sleep disturbances. Blinding was achieved by running a strategic matched placebo parallel group. Co-primary outcome measures were the changes between baseline and end of the treatment period in sleep maintenance/efficiency as assessed by polysomnography and the Parkinson's Disease Sleep Scale Version 2 (PDSS-2) score.

RESULTS

A total of 20 of 30 patients were randomized to rasagiline (mean ± SD age, 69.9 ± 6.9 years; 10 male; Hoehn-Yahr stage, 1.9 ± 0.8). Compared with baseline, sleep maintenance was significantly increased at the end of the treatment period (relative change normalized to baseline, +16.3 ± 27.9%; P = 0.024, paired two-sided t-test) and a positive trend for sleep efficiency was detected (+12.1 ± 28.6%; P = 0.097). Treatment with rasagiline led to significantly decreased wake time after sleep onset, number of arousals, percentage of light sleep and improved daytime sleepiness as measured by the Epworth Sleepiness Scale. We did not observe changes in the co-primary endpoint PDSS-2 score, and no correlations of polysomnographic sleep parameters or PDSS-2 score with motor function (Unified Parkinson's Disease Rating Scale motor score). Rasagiline was well tolerated with no unexpected adverse events.

CONCLUSIONS

In patients with PD with sleep disturbances, rasagiline showed beneficial effects on sleep quality as measured by polysomnography. These effects were probably not related to motor improvement or translated into improved overall sleep quality perception by patients.

摘要

背景与目的

本研究旨在探讨雷沙吉兰对伴有睡眠障碍的帕金森病(PD)患者睡眠质量的影响。睡眠障碍在 PD 中很常见。雷沙吉兰广泛用于 PD 患者,但关于其对睡眠障碍影响的双盲多导睡眠图试验尚缺乏。

方法

这是一项在伴有睡眠障碍的 PD 患者中进行的为期 8 周、单中心、双盲、以基线为对照、由研究者发起的雷沙吉兰(1mg/天)临床试验。通过运行策略性匹配安慰剂平行组实现了盲法。主要疗效指标为多导睡眠图和帕金森病睡眠量表第 2 版(PDSS-2)评分评估的睡眠维持/效率在基线和治疗期末之间的变化。

结果

共有 30 例患者中的 20 例被随机分配至雷沙吉兰组(平均年龄±标准差,69.9±6.9 岁;10 例男性;Hoehn-Yahr 分期,1.9±0.8)。与基线相比,治疗期末的睡眠维持显著增加(相对于基线的相对变化,+16.3±27.9%;P=0.024,配对双侧 t 检验),睡眠效率呈正趋势(+12.1±28.6%;P=0.097)。雷沙吉兰治疗可显著减少睡眠后觉醒时间、觉醒次数、浅睡眠百分比和改善日间嗜睡(Epworth 嗜睡量表评估)。我们未观察到 PDSS-2 评分这一首要终点的变化,并且多导睡眠图睡眠参数或 PDSS-2 评分与运动功能(统一帕金森病评定量表运动评分)之间无相关性。雷沙吉兰耐受良好,无意外不良事件发生。

结论

在伴有睡眠障碍的 PD 患者中,雷沙吉兰在多导睡眠图测量的睡眠质量方面显示出有益作用。这些作用可能与运动改善无关,也未转化为患者对整体睡眠质量感知的改善。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验